nach oben

Erschienen in:

01.03.2010 | Original Article

Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8

verfasst von: Ann E. Kearns, Donald W. Northfelt, Amylou C. Dueck, Pamela J. Atherton, Shaker R. Dakhil, Kendrith M. Rowland Jr, Jyotsna Fuloria, Patrick J. Flynn, Todor Dentchev, Charles L. Loprinzi

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer.

Materials and methods

This is a randomized placebo-controlled trial of risedronate and estradiol, alone or in combination, in men with prostate cancer receiving androgen deprivation therapy. The primary outcome was change in hip bone mineral density at 1 year.

Results

No statistical difference was found among the groups for bone mineral density changes. The only side effects of note were increased gynecomastia and breast tenderness associated with estrogen therapy. The study was limited by poor accrual and subsequent lack of statistical power.

Conclusions

Men receiving androgen deprivation therapy for prostate cancer are at risk for bone loss and should receive appropriate bone density monitoring and preventive advice about calcium, vitamin D, exercise, and fall prevention. Prescription drugs proven in this patient population should be used when the risk of fracture is high.

Stoch SA, Parker RA, Chen L et al (2001) Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86:2787–2791. doi:10.1210/jc.86.6.2787 CrossRefPubMed

Greenspan SL, Coates P, Sereika SM et al (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410–6417. doi:10.1210/jc.2005-0183 CrossRefPubMed

Shahinian VB, Kuo YF, Freeman JL et al (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164. doi:10.1056/NEJMoa041943 CrossRefPubMed

Smith MR, Lee WC, Brandman J et al (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23:7897–7903. doi:10.1200/JCO.2004.00.6908 CrossRefPubMed

Smith EP, Boyd J, Frank GR et al (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056–1061. doi:10.1056/NEJM199410203311604 CrossRefPubMed

Morishima A, Grumbach MM, Simpson ER et al (1995) Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689–3698. doi:10.1210/jc.80.12.3689 CrossRefPubMed

Gennari L, Merlotti D, Martini G et al (2003) Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 88:5327–5333. doi:10.1210/jc.2003-030736 CrossRefPubMed

Khosla S, Melton LJ 3rd, Atkinson EJ et al (2001) Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86:3555–3561. doi:10.1210/jc.86.8.3555 CrossRefPubMed

Szulc P, Munoz F, Claustrat B et al (2001) Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 86:192–199. doi:10.1210/jc.86.1.192 CrossRefPubMed

10.

Meier C, Nguyen TV, Handelsman DJ et al (2008) Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 168:47–54. doi:10.1001/archinternmed.2007.2 CrossRefPubMed

11.

Mellstrom D, Vandenput L, Mallmin H et al (2008) Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 23:1552–1560. doi:10.1359/jbmr.080518 CrossRefPubMed

12.

Falahati-Nini A, Riggs BL, Atkinson EJ et al (2000) Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553–1560. doi:10.1172/JCI10942 CrossRefPubMed

13.

Michaelson MD, Kaufman DS, Lee H et al (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038–1042. doi:10.1200/JCO.2006.07.3361 CrossRefPubMed

14.

Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948–955. doi:10.1056/NEJMoa010845 CrossRefPubMed

15.

Greenspan SL, Nelson JB, Trump DL et al (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146:416–424PubMed

16.

Smith MR, Malkowicz SB, Chu F et al (2008) Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179:152–155. doi:10.1016/j.juro.2007.08.137 CrossRefPubMed

17.

Smith MR, Fallon MA, Lee H et al (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841–3846. doi:10.1210/jc.2003-032058 CrossRefPubMed

18.

Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 31:103–115. doi:10.2307/2529712 CrossRefPubMed

19.

Hilton JF, Mehta CR (1993) Power and sample size calculations for exact conditional tests with ordered categorical data. Biometrics 49:609–616. doi:10.2307/2532573 CrossRefPubMed

20.

Shapiro SS, Wilk MB (1965) An analysis of variance test for normality. Biometrika 52:591–611

21.

Kiralti BJ (2001) Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57:127–132

22.

Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243–3253. doi:10.1001/jama.289.24.3243 CrossRefPubMed

Titel: Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8
verfasst von: Ann E. Kearns
Donald W. Northfelt
Amylou C. Dueck
Pamela J. Atherton
Shaker R. Dakhil
Kendrith M. Rowland Jr
Jyotsna Fuloria
Patrick J. Flynn
Todor Dentchev
Charles L. Loprinzi
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 3/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-009-0655-x

Springer Medizin

Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8